All articles by stevebarrett


SAN FRANCISCO — Empagliflozin has a consistent cardioprotective effect in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), regardless of the number of CV risk factors that are controlled, according to research presented at the 79th Scientific Sessions of the American Diabetes Association, held June 7 to 11, 2019, in San Francisco. Researchers…